Investor Presentation

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 August 5, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Investors Presentation on Financial Results of the Company for the quarter ended June 30, 2026 Please find enclosed the Investors Presentation on Financial Results of the Company for the quarter ended June 30, 2026. You are requested to take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA Company Secretary & Compliance Officer Encl.: As above Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 Amanta Healthcare Limited Q1FY27 Investor Presentation August, 2026 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Amanta Healthcare Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containingdetailedinformationabouttheCompany. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation.ThisPresentationmaynotbeallinclusiveandmaynotcontainalloftheinformationthatyoumayconsidermaterial.Anyliabilityinrespectofthecontentsof,orany omissionfrom, thisPresentation isexpresslyexcluded.Certain mattersdiscussed inthisPresentation maycontain statementsregardingtheCompany’s market opportunityand businessprospectsthat areindividually and collectivelyforward-looking statements.Such forward-looking statementsarenotguaranteesoffutureperformanceand aresubject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, incomeorcashflows,theCompany’s market preferencesand itsexposuretomarket risks,aswellasother risks.TheCompany’s actualresults,levels ofactivity,performanceor achievementscould differmateriallyand adverselyfromresultsexpressedinorimpliedbythisPresentation.TheCompanyassumes noobligationtoupdate anyforward-looking information containedinthisPresentation.Any forward-looking statementsand projections made bythird parties includedinthisPresentation arenotadoptedbythe Company andtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections. NICHE PHARMACEUTICAL COMPANY OPERATION AL METRICS FIN ANCIAL METRICS REVENUE CAGR EBITDA CAGR 1 7 47 30+ Years of 11% 10% WHO-GMP facility Production lines Product portfolio FY21–26 FY21–26 Sterile Liquids 6 320 21 ROE ROCE Legacy Therapeutic Distributors & Countries exported 8.9% 11.1% segments stockists FY26 FY26 120 30 506 DEBT TO EQUITY Intl. jurisdictions Years in business Team size 3.50× 1.06× FY23 to FY26 —improving Integrated LVPs & SVPs manufacturer NET WORKING CAPITAL DAYS SteriPort 141 days Established generic brand FY26 Widely used in hospitals Critical medications Respiratory Irrigation Advanced tech IV Fluids Diluents Ophthalmic Formulations Care Solutions ABFS & ISBM across 6 therapeutic segments Built to scale – Amanta’s differentiated business model RM Sourcing Manufacturing Capabilities 3 Channel Distribution Manufacturing facilityin Gujarat Key materials Sourced spanning 66,852 sq. mts Robust sales and distribution team with strong presence across the globe 18.5% LVP 4 lines SVP 3 lines 27.5% TWO PORT 12.5% Branded products domestically LDPE CLOSURE POLYPROPYLENE Total Capacity : 12.28 crore Total Capacity : 20.91 crore through320+distributors SYSTEM 2 Lines : Conventional Single 2 Lines: ABFS port bottles Geographical concentration of Plastic 2 Lines : Steriportwith ISBM 1 Line : Conventional 3- technology piece container Purchase Exports to emerging and Fluid Therapy semi-regulated markets (IV Fluid) Ophthalmics 22.8% Product Partnering Formulations Therapeutic Respiratory 77.2% segments Solutions Portfolio expansion in markets such South Korea Thailand as UK, Latin America, South East Asia Irrigation Diluents & & Africa Top 10 suppliers account for 76% of materials Solutions Injectables consumed Solutions : A Diverse Product Portfolio (1/2) NotableFormulations : TypesofIVFluids : Diluent Product Overview : Dextrose, Normal Saline, Combination Of Ciprofloxacin, Metronidazole, Ofloxacin, • PlainWaterforInjection(WFI) Dextrose Normal Saline, Ringer Lactate, Paracetamol, Fluconazole. • Normal Saline Electrolytes. PackagingOptions : Diluents Pack Sizes : • LargeVolume Parenterals(LVPs) PackagingOfProduct : Offered in 5 ml & 10 ml • SmallVolume Parenterals(SVPs) Single Port Container, TwoPort Container Injectables Portfolio Key Products : FillVolumeRange : FillVolumeOptions : Lidocaine, Potassium Chloride, Magnesium 2mlto100ml 100ml, 250ml, 500ml, 1000ml. Sulphate, Calcium Chloride, Calcium Technology : Gluconate InnovativeTechnology : Aseptic Blow-Fill-Seal (ABFS) Amanta manufactures SteriPort bottles for & InjectionStretch BlowMoulding (ISBM) IV fluids using ISBM Technology, with technology polypropylene as the rawmaterial Diluents & Injectables Fluid Therapy Formulations Revenue share across all categories 5 Solutions : A Diverse Product Portfolio (2/2) Applications : Applications : Product Types : Administered through nebulisers for the treatment Treatment for Infections, Glaucoma, OTC Eye Lubricants of lungs affected by Asthma or Bronchiectasis Inflammation. Wound Cleaning Solutions Dosage Form : Dosage Forms : Available in 2.5 ml Dosage Forms : 5ml & 10 ml Key Products : Available in 5 ml, 10 ml & 20 ml Respiratory Suspension Packaging Options : Product : Budesonide, Salbutamol • Form Fill Seal (FFS) Pack • Sodium Chloride Eye Wash •Salbutamol & Ipratropium Bromide • Three-Piece Conventional Pack •Levosalbutamol • Wound Cleaning Levosalbutamol & Ipratropium 5% 5% Opthalmic Respiratory Solutions Irrigation Solutions Core Competitive Advantages PRODUCTS & MARKETS DISTRIBUTION Driving Success Well-established Wide Domestic & Pharma Manufacturer Global Network Products Six therapeutic segments and container systems. 47 Pan-India network of 320 distributors, 96 sales staff, products registered in 120 countries across LVPs and Countries and integrated IT systems across 21 export markets. SVPs. 47 Products 320 Distributors Years INFRASTRUCTURE HUMAN CAPITAL Scaled-up Manufacturing Leadership & Capabilities Skilled Workforce Management team with 30+ years of experience, Gujarat facility spanning 66,852 sq. meters with Aseptic supported by 506 employees (≈1,700 with contract BFS and ISBM technologies. ISO & WHO-GMP certified. workers). 66,852 sq.m 506 Employees Differentiated Manufacturing Technologies to Market End Product First to bring ISBM technology to India TECHNOLOGY 01 TECHNOLOGY 02 SUPPORT SYSTEM Aseptic Blow Injection Stret [Showing first 8,000 characters — download PDF for full document]